Illinois pharmacists to lock painkiller scripts
Illinois legislators recently approved a pilot program that would place locking devices on some prescription painkillers.
Illinois legislators recently approved a pilot program that would place locking devices on some prescription painkillers.
Related: [BLOG]: Use and abuse of opioids: FDA responds
House Bill 3219 instructs the Department of Financial and Professional Regulation to implement a pilot project requiring that every new or refilled prescription for a Schedule II controlled substance containing hydrocodone shall only be dispensed in a non-reusable medicine locking closure package. Numerical locking devices, similar to those used on gym lockers, would be put on prescription bottles, according to an Associated Pressarticle.
H.B. 3219 says the medicine locking closure package must be dispensed by the pharmacy with instructions for patient use. However, it exempts prescriptions reimbursed via Medicare Part D and Medicaid and prescriptions, “for individuals residing in facilities licensed under the Nursing Home Care Act.”
Related:Once-daily opioid formulated with abuse-deterrent properties now available
If signed by Illinois Governor Bruce Rauner, the law will go into effect January 1, 2016. The Department can spend up to $150,000 on the pilot project.
State Rep. Mike Zalewski sponsored the bill because, he says, a more aggressive approach is needed to fight addiction and substance abuse, the article stated.
Read next: PCORI awards prison system $2M to study naltrexone benefit in opioid abuse
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
